Phase 2
Completed N=18
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Source: ClinicalTrials.gov NCT01408732 ↗
Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcomePrimary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Summary
The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Severityof Epistaxis |
-0.4578; -1.4375 | — |
Eligibility Criteria
Inclusion Criteria
- a clinical diagnosis of HHT based on the Curacoa Criteria
- age 18 and older
- cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires
Exclusion Criteria
- previous sclerotherapy with Sodium Tetradecyl Sulfate
Data sourced from ClinicalTrials.gov (NCT01408732). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.